Overview

* TransMedics ( TMDX ) Q3 revenue grows 32% yr/yr but misses analyst expectations

* Net income for Q3 rises to $24.3 mln, reflecting strong operational performance

* Company announces collaboration with Mercedes-Benz for organ transport in Italy

Outlook

* TransMedics ( TMDX ) raises 2025 revenue guidance to $595 mln-$605 mln

* Company aims to end 2025 strongly and prepare for growth in 2026

* TransMedics ( TMDX ) plans to deploy Mercedes-Benz vehicles for organ transport in Italy

Result Drivers

* OCS UTILIZATION - Revenue growth driven by increased utilization of Organ Care System, particularly in Liver and Heart through NOP

* R&D INVESTMENT - Operating expenses rose due to increased R&D investment and organizational growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $143.80 $145.20

Revenue mln mln (10

Analysts

)

Q3 Net $24.30

Income mln

Q3 Gross 59%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Transmedics Group Inc ( TMDX ) is $146.50, about 11.5% above its October 28 closing price of $129.71

* The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 62 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)